For example Lirilumab, the monoclonal antibody that binds KIR, is currently in a phase II clinical trial for lymphoma.237 By blocking the interaction of inhibitory KIR with their HLA class I ligands this antibody facilitates activation of NK cells by impeding inhibitory signalling, potentially promoting destruction of tumour cells. The gene discussed is KIR3DL1; the disease is lymphoma.